Laura C Godfrey

Dr. Laura C Godfrey

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
LGLaura C Godfrey
Laura C Godfrey
NCNicholas T. Crump
Nicholas T. Crump
RTRoss Thorne
Ross Thorne
ILI-Jun Lau
I-Jun Lau
EREmmanouela Repapi
Emmanouela Repapi
TMTom Milne
Tom Milne
Enhancer elements are a key regulatory feature of many important genes. Several general features including the presence of specific histone modifications are used to demarcate potentially active enhancers. Here we reveal that putative enhancers marked with H3 lysine 79 (H3K79) di or trimethylation (me2/3) (which we name H3K79me2/3 enhancer elements or KEEs) can be found in multiple cell types. Mixed lineage leukemia gene (MLL) rearrangements (MLL-r) such as MLL-AF4 are a major cause of incurable acute lymphoblastic leukemias (ALL). Using the DOT1L inhibitor EPZ-5676 in MLL-AF4 leukemia cells, we show that H3K79me2/3 is required for maintaining chromatin accessibility, histone acetylation and transcription factor binding specifically at KEEs but not non-KEE enhancers. We go on to show that H3K79me2/3 is essential for maintaining enhancer-promoter interactions at a subset of KEEs. Together, these data implicate H3K79me2/3 as having a functional role at a subset of active enhancers in MLL-AF4 leukemia cells.

1 December 2015 in Cell Reports
Verified
Journal Article
Open access
JBJuliana M. Benito
Juliana M. Benito
LGLaura C Godfrey
Laura C Godfrey
KKKensuke Kojima
Kensuke Kojima
LHLeah Hogdal
Leah Hogdal
MWMark Wunderlich
Mark Wunderlich
MKMarina Konopleva
Marina Konopleva
Targeted therapies designed to exploit specific molecular pathways in aggressive cancers are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as the t(4;11) translocation cause aggressive leukemias that are refractory to conventional treatment. The t(4;11) translocation produces an MLL/AF4 fusion protein that activates key target genes through both epigenetic and transcriptional elongation mechanisms. In this study, we show that t(4;11) patient cells express high levels of BCL-2 and are highly sensitive to treatment with the BCL-2-specific BH3 mimetic ABT-199. We demonstrate that MLL/AF4 specifically upregulates the BCL-2 gene but not other BCL-2 family members via DOT1L-mediated H3K79me2/3. We use this information to show that a t(4;11) cell line is sensitive to a combination of ABT-199 and DOT1L inhibitors. In addition, ABT-199 synergizes with standard induction-type therapy in a xenotransplant model, advocating for the introduction of ABT-199 into therapeutic regimens for MLL-rearranged leukemias.

5 August 2019 in Blood
Verified
Journal Article
Closed access
SOSorcha O’bYrne
Sorcha O’bYrne
NENatalina Elliott
Natalina Elliott
SRSiobhan Rice
Siobhan Rice
GBGemma Buck
Gemma Buck
NFNicholas Fordham
Nicholas Fordham
ARAnindita Roy
Anindita Roy
By comparing fetal and adult B-lymphopoiesis, the authors identify a prepro–B-cell subset in humans that marks the origin of B-cell lineage commitment in utero.

1 January 2017 in Cell Reports
Verified
Journal Article
Open access
JKJon Kerry
Jon Kerry
LGLaura C Godfrey
Laura C Godfrey
EREmmanouela Repapi
Emmanouela Repapi
MTMarta Tapia
Marta Tapia
NBNeil P. Blackledge
Neil P. Blackledge
TMTom Milne
Tom Milne
Understanding the underlying molecular mechanisms of defined cancers is crucial for effective personalized therapies. Translocations of the mixed-lineage leukemia (MLL) gene produce fusion proteins such as MLL-AF4 that disrupt epigenetic pathways and cause poor-prognosis leukemias. Here, we find that at a subset of gene targets, MLL-AF4 binding spreads into the gene body and is associated with the spreading of Menin binding, increased transcription, increased H3K79 methylation (H3K79me2/3), a disruption of normal H3K36me3 patterns, and unmethylated CpG regions in the gene body. Compared to other H3K79me2/3 marked genes, MLL-AF4 spreading gene expression is downregulated by inhibitors of the H3K79 methyltransferase DOT1L. This sensitivity mediates synergistic interactions with additional targeted drug treatments. Therefore, epigenetic spreading and enhanced susceptibility to epidrugs provides a potential marker for better understanding combination therapies in humans.

14 November 2016 in Experimental Hematology
Verified
Journal Article
Open access
PDF file
LGLaura C Godfrey
Laura C Godfrey
JKJon Kerry
Jon Kerry
RTRoss Thorne
Ross Thorne
EREmmanouela Repapi
Emmanouela Repapi
JDJames O.J. Davies
James O.J. Davies
TMTom Milne
Tom Milne
Survival rates for children and adults carrying mutations in the Mixed Lineage Leukemia (MLL) gene continue to have a very poor prognosis. The most common MLL mutation in acute lymphoblastic leukemia is the t(4;11)(q21;q23) chromosome translocation that fuses MLL in-frame with the AF4 gene producing MLL-AF4 and AF4-MLL fusion proteins. Previously, we found that MLL-AF4 binds to the BCL-2 gene and directly activates it through DOT1L recruitment and increased H3K79me2/3 levels. In the study described here, we performed a detailed analysis of MLL-AF4 regulation of the entire BCL-2 family. By measuring nascent RNA production in MLL-AF4 knockdowns, we found that of all the BCL-2 family genes, MLL-AF4 directly controls the active transcription of both BCL-2 and MCL-1 and also represses BIM via binding of the polycomb group repressor 1 (PRC1) complex component CBX8. We further analyzed MLL-AF4 activation of the BCL-2 gene using Capture-C and identified a BCL-2-specific enhancer, consisting of two clusters of H3K27Ac at the 3′ end of the gene. Loss of MLL-AF4 activity results in a reduction of H3K79me3 levels in the gene body and H3K27Ac levels at the 3′ BCL-2 enhancer, revealing a novel regulatory link between these two histone marks and MLL-AF4-mediated activation of BCL-2.

1 September 2025 in EMBO Reports
Verified
Journal Article
Open access
LGLaura C Godfrey
Laura C Godfrey
BRBrandon Regalado
Brandon Regalado
SSSydney R Schweber
Sydney R Schweber
CHCharles Hatton
Charles Hatton
DWDaniela Vanessa Wenge
Daniela Vanessa Wenge
SAScott A Armstrong
Scott A Armstrong
The t(11;22) translocation encodes the EWS::FLI1 fusion oncoprotein which is the primary driver of Ewing sarcoma. EWS::FLI1 creates unique, de novo pathogenic enhancers that drive gene expression and are a central mechanism of oncogenesis. Which chromatin regulatory proteins are critical to this mechanism is understudied. Here, we perform a comparative analysis of the function of the chromatin complexes MLL3/4 and p300/CBP in EWS::FLI1-mediated gene regulation. Using EWS::FLI1 degradation models, we define a subset of EWS::FLI1-sensitive enhancers whose activity correlates with p300/CBP function. We perturb both chromatin complexes to establish that in contrast to MLL3/4, p300/CBP is a critical regulator of EWS::FLI1-driven enhancer activity and downstream gene expression. We also show that p300/CBP small-molecule inhibition decelerates tumor growth in vivo. Our work highlights the context-dependent nature of chromatin protein activity at oncogenic enhancers and reveals p300/CBP as an important regulator of Ewing sarcoma.